Obstructive hypertrophic cardiomyopathy. Pathophysiology and clinical management by Almaas, Vibeke Marie
 Obstructive hypertrophic cardiomyopathy 
Pathophysiology and clinical management 
by 
Vibeke Marie Almaas 
Department of Cardiology,  
Oslo University Hospital, Rikshospitalet 
Faculty of Medicine, University of Oslo, Norway 
2015 

























9LEHNH0DULH$OPDDV

Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 2078 
,6%1


$OOULJKWVUHVHUYHG1RSDUWRIWKLVSXEOLFDWLRQPD\EH
UHSURGXFHGRUWUDQVPLWWHGLQDQ\IRUPRUE\DQ\PHDQVZLWKRXWSHUPLVVLRQ








&RYHU+DQQH%DDGVJDDUG8WLJDUG
3ULQWSURGXFWLRQ-RKQ*ULHJ$6%HUJHQ

3URGXFHGLQFRRSHUDWLRQZLWK$NDGHPLND3XEOLVKLQJ
7KHWKHVLVLVSURGXFHGE\$NDGHPLND3XEOLVKLQJPHUHO\LQFRQQHFWLRQZLWKWKH
WKHVLVGHIHQFH.LQGO\GLUHFWDOOLQTXLULHVUHJDUGLQJWKHWKHVLVWRWKHFRS\ULJKW
KROGHURUWKHXQLWZKLFKJUDQWVWKHGRFWRUDWH

3 
 
TABLE OF CONTENTS 
1. Acknowledgements 
2. List of Papers 
3. Abbreviations 
4. Introduction 
5. Aims of the Thesis 
6. Patients and methods 
6.1. Patient population 
6.2. Scandinavian HOCM database 
6.3. Genetic testing 
6.4. Exercise test 
6.5. Holter monitoring 
6.6. Risk stratification and definition of ventricular arrhythmias 
6.7. Echocardiography  
6.8. Cardiac magnetic resonance 
6.9. PTSMA 
6.10. Myectomy 
6.11. Histologic examination of the operation specimens 
6.12. Statistical analysis 
7. Summary of results 
7.1. Paper I 
4 
7.2. Paper II 
7.3. Paper III 
7.4. Paper IV 
8. Discussion
8.1. The HCM population – one diagnosis – several diseases?
8.2. Fibrosis
8.3. Arrhythmias, LGE and strain
8.4. Myocardial function
8.5. Septal reduction therapy
8.6. Future perspective
9. Conclusions
10. Reference List
5 
 
1. ACKNOWLEDGEMENTS 
The present work was carried out at the Medical Outpatient Clinic, Department of Medicine, 
Oslo University Hospital, Rikshospitalet during the years November 2004 – December 2010 
when I was working as a clinical research fellow at Institute of Clinical Medicine, Faculty of 
Medicine, University of Oslo.  In January 2011 I started as a junior registrar at the 
Department of Cardiology, Oslo University Hospital, Rikshospitalet, where I am still working. 
The thesis was completed in January 2015. The work was supported by Inger and John 
Fredriksen`s Heart Foundation.  
I have been privileged to have supervisors with excellent research and cardiological 
experience. I am very grateful to my main supervisor prof. dr. med. Jan P. Amlie who 
introduced me to the research field “hypertrophic cardiomyopathy”. I was happy to continue 
the research project on patients with hypertrophic cardiomyopathy, initiated by Ole-Gunnar 
Anfinsen MD, PhD some years earlier. Jan Amlie was very enthusiastic and gave me wise 
advices and comments – always in a friendly tone. In my daily work as a research fellow, 
often occupied by distracting details, Amlie taught me to catch up the great lines. After 
Amlie was retired in 2012, he continued to take an active part in the project work until he 
unfortunately passed away in May 2014. Prof. dr. med. Halfdan Ihlen was my co-supervisor 
and introduced me at the Echocardiographic Laboratory. In 2006 he retired and was 
replaced by prof. dr. med. Svend Aakhus first as a co-supervisor and later as my main 
supervisor. I am very grateful for having been given the opportunity to learn from Svend 
Aakhus’ excellent skills in echocardiography and hemodynamic, and his genuine research 
knowledge. His clinical cardiological experience and practical approach have had a major 
impact on the project. Prof. Thor Edvardsen MD PhD has been co-supervisor the last year. I 
am very grateful for Thor Edvardsen’s excellent research knowledge, support and advices in 
the work with cardiac magnetic imaging and strain echocardiography.  
I want to thank Helge Skulstad MD PhD for learning me and giving me invaluable help with 
the ergometric stress-echocardiographic examinations, and for positive support and 
comments. Echo-technician Pia Bryde thoroughly taught me the ordinary echocardiographic 
examination; thank you very much. Special thanks to Prof. dr. med. Odd Geiran at the 
Department of Thoracic Surgery who has performed most of the myectomies and to dr. 
med. Knut Endresen at Department of Cardiology that performed all the PTSMA procedures. 
Thank you for your enthusiasm and support to the project. I am very grateful to Ole-Gunnar 
Anfinsen MD PhD who started and has followed the project, and for his invaluable help in 
the writing process. A special thanks to my colleague and friend Christen Dahl MD PhD for 
ensuring that the myectomy specimens were correctly processed in the operation room, 
whenever it happened! I would like to express my gratitude to prof. dr. med. Helge Scott and 
Erik Strøm MD at Department of Pathology for important and generous contributions to the 
project by excellent histological analyses of the myectomy specimens, and for interesting 
6 
discussions. Professor dr. med. Hans-Jørgen Smith did an excellent work with the cardiac 
magnetic resonance analyses and prof. dr. med. Trond Leren and Knut Erik Berge MD PhD at 
Department of Medical Genetics contributed to the project by handling the genetic analyses. 
Many thanks to special nurse Maj-Britt Skåle and to research nurse Rita Skårdal for your 
contribution to the project. Professor dr. med. Lars Gullestad has excellent experience in 
research biobank and your support and advices have been invaluable. The project included 
three visits at the Medical Outpatient Clinic in addition to the admission related to the septal 
reduction therapy. I am very grateful to Grete Jacobsen, secretary at Medical Outpatient 
Clinic, for the enormous logistic work you did to coordinate several clinical examinations.  
Through the project I have had the opportunity to be a part of a Scandinavian clinical 
research collaboration initiated by Morten Kvistholm Jensen MD PhD and prof. Henning 
Bundgaard MD PhD at Department of Cardiology, Rigshospitalet in Copenhagen. From their 
first visit in Oslo in 2005 and today we have had, together with prof.  Fredrik Gadler MD PhD, 
associate prof. Maria Ericsson MD PhD and Linda Jacobsson MD at Karolinska University 
Hospital in Stockholm, a very constructive and friendly collaboration in building up 
“Scandinavian HOCM database”. I am looking forward to continuing our ongoing scientific 
collaboration on HCM-patients and PTSMA treatment.      
I am very grateful to my colleague and friend ass. prof. Kristina Haugaa MD PhD for your 
enthusiasm and support to the project, for interesting discussions and for invaluable help in 
the writing process. I am looking forward to continue our collaboration. Thank you all my 
colleagues at the Department of Cardiology for friendship and support, and special thanks to 
Marit Aarønæs MD PhD who I shared office with during the research-fellow period.      
Finally, I want to thank my family. Thanks to my positive and creative father and to my 
generous and supporting parents in law. Unfortunately, I cannot show this thesis to my 
mother who died several years ago. I know she would like to follow my work during these 
years. Thank you to my children Morten and Aurora and my husband Runar for always being 
impatient. Runar told me that if I "thank you for reminding me of the essence of life" you 
surely will do. So: I will not. Thank you anyway. 
7 
 
2. LIST OF PAPERS 
I Vibeke M. Almaas, Kristina H. Haugaa, Erik H. Strøm, Helge Scott, Christen P. Dahl, 
Trond P. Leren, Odd R. Geiran, Knut Endresen, Thor Edvardsen, Svend Aakhus, Jan 
Peder Amlie. Increased amount of interstitial fibrosis predicts ventricular 
arrhythmias, and is associated with reduced myocardial septal function in patients 
with obstructive hypertrophic cardiomyopathy. Europace. 2013;15:1319–1327. 
 
II Vibeke M. Almaas, Kristina H. Haugaa, Erik H. Strøm, Helge Scott, Hans-Jørgen Smith, 
Christen P. Dahl, Odd R. Geiran, Knut Endresen, Svend Aakhus, Jan Peder Amlie, Thor 
Edvardsen. Non-invasive assessment of myocardial fibrosis in patients with 
obstructive hypertrophic cardiomyopathy. Heart. 2014;100:631-638. 
 
III Vibeke M. Almaas, Helge Skulstad, Ole-Gunnar Anfinsen, Knut Endresen, Odd R. 
Geiran, Jan Peder Amlie, Svend Aakhus. Impaired diastolic function in obstructive 
hypertrophic cardiomyopathy  patients with non-successful percutaneous 
transluminal septal myocardial ablation. Submitted. 
 
IV Jensen MK, Almaas VM, Jacobsson L, Hansen PR, Havndrup O, Aakhus S, Svane B, 
Hansen TF, Kober L, Endresen K, Eriksson MJ, Jorgensen E, Amlie JP, Gadler F, 
Bundgaard H. Long-term outcome of percutaneous transluminal septal myocardial 
ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter 
study. Circ Cardiovasc Interv. 2011;4:256-265. 
8 
 
3. ABBREVIATIONS 
2D   two-dimensional 
AFOG   acid fucsin orange-G 
CAD   coronary artery disease 
CK  creatine kinase 
CK-MB  creatine kinase muscle-brain 
ECG  electrocardiogram 
EF   ejection fraction 
HCM   hypertrophic cardiomyopathy 
ICD  implantable cardioverter defibrillator 
IVSd  interventricular septal dimension 
LGE  late gadolinium enhancement 
LGE-CMR  late gadolinium enhancement cardiac magnetic resonance 
LV   left ventricle 
LVOT  left ventricular outflow tract 
MWT   maximal wall thickness 
NSVT   non-sustained ventricular tachycardia 
NYHA  New York Heart Association 
PTSMA  percutaneous transluminal septal myocardial ablation 
ROC   receiver operating characteristic 
ROI  region of interest 
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SAM   systolic anterior motion 
SCD  sudden cardiac death 
SD   standard deviation 
STE  speckle tracking echocardiography 
VT   ventricular tachycardia 
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4. INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a common global genetic cardiovascular disease with 
a heterogeneous clinical spectre. The reported prevalence is 0.02 – 0.2% (1:5000 – 1:500).1-4 
These figures will translate into 1000 - 10 000 individuals affected in Norway, exceeding the 
number of patients actually discovered. Thus many affected individuals are undiagnosed 
probably without symptoms and with normal life expectancy, but in some patients the 
disease progression results in significant complications. 5 The most frightened complication 
is sudden unexpected death.  
An autosomal dominant mutation in a gene encoding thick or thin myofilament proteins or 
Z-disc proteins of the cardiac sarcomere (i.e. sarcomere-gene mutations) is identified in
approximately 60-70% of the HCM-patients with a positive family history, and in
approximately 10-50% of the HCM-patients without a family history.6,7
Figure 4.1. Genotype positive patients mean that a HCM related mutation is identified, and 
genotype negative that a HCM related mutation not is identified. Genotype positive patients 
get the HCM-diagnosis when left ventricle (or right ventricle) wall thickness is measured ≥13 
mm. Genotype negative patients get the HCM-diagnosis when wall thickness is measured
≥15 mm.
The American guidelines from 2011 emphasize that the diagnose HCM is linked to left 
ventricular hypertrophy with a sarcomere mutation identified or a genetic substrate 
unresolved but unexplained left ventricular hypertrophy ≥15 mm without extracardiac or 
11 
 
metabolic findings.2 Unlike the American guidelines from 2011 the European guidelines from 
2014 use a purely morphological disease definition of HCM with the possibility of a number 
of aetiologies: “HCM is defined by the presence of increased left ventricle wall thickness (≥15 
mm) that is not solely explained by abnormal loading conditions.”4 In these guidelines HCM 
is defined by specific morphological criteria and then grouped into familial/genetic or non-
familial/non-genetic subtypes, irrespective of the presence of extra-cardiac diseases.  
 
Autopsy-reports from patients suffering sudden cardiac death (SCD) and histological 
evaluations of explanted hearts from HCM-patients with end-stage heart failure have 
demonstrated the histopathological hallmarks of HCM with myocyte hypertrophy, regions of 
myocyte disarray, different types of fibrosis, and small vessel disease.9 Myocyte disarray is 
characterized by regions of disorganized myocytes arranged obliquely or perpendicularly to 
each other with scattered areas of interstitial fibrosis (named plexiform fibrosis by Anderson 
et al in 1979). 10 Whereas myocyte disarray is present in several cardiovascular diseases, the 
amount of disarray in HCM is substantially higher (5-10% of the ventricular septum).11 In the 
majority of cases, myocyte disarray is extensive and >20% of the myocardium will exhibit 
disarray in at least two histopathological tissue blocks.11 It has been argued that myocyte 
disarray is the arrhythmogenic substrate in young HCM-patients9, and that increased 
amount of myocyte disarray is associated with diastolic dysfunction.12,13 Both macroscopic 
and microscopic fibrosis are described in HCM-patients.14 Macroscopic scars are grey or 
white small patchy or large transmural scars most pronounced in the septum.15 The 
myocardial ischemia in HCM-patients is usually unrelated to atherosclerotic coronary artery 
disease, but rather caused by supply-demand mismatch due to left ventricle (LV) 
hypertrophy with increased oxygen demand and adverse loading conditions. The myocardial 
ischemia is followed by medial hypertrophy and luminal narrowing of the intramural 
arterioles, thickening of these walls, and subsequently, causes compromised intramural 
blood flow.16-18  
Anderson et al described different types of microscopic fibrosis: replacement fibrosis, 
interfibre fibrosis, perivascular fibrosis and plexiform fibrosis in 1979.19 Until recently the 
vast majorities of the studies reported total amount of fibrosis and the studies were largely 
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concerned with the ischemic type of fibrosis (replacement fibrosis). Replacement fibrosis 
may be a result of small vessel disease, remodelling and longstanding disease, and is 
increased in patients with heart failure and end stage HCM.18 Recently, there has been an 
increased focus on the collagen network that builds up the structural skeletal framework of 
the extracellular matrix (diffuse interstitial fibrosis).20 Young HCM-patients have increased 
amount of collagen and the morphology of the collagen network is abnormal.21  The role of 
this diffuse interstitial fibrosis has received less attention, but its role in HCM related 
arrhythmogenesis is increasingly recognized.  
Patients with HCM have obviously reduced myocardial function due to several 
pathophysiological factors as myocyte hypertrophy, myocardial disarray, myocardial fibrosis, 
and sarcomere mutations associated with structural abnormalities and possible force 
generation deficiency. These factors may not influence on myocardial ability of reduction of 
LV cavity volume, and thereby EF is maintained in these patients.22 Newer echocardiographic 
methods as myocardial strain assessment have the ability to detect reduced segmental and 
global myocardial systolic function.23-27 Strain-measurements by tissue-Doppler 
echocardiography were first validated by Urheim et al in 2000.27 Compared to normal, Yang 
et al described in 2003 reduced longitudinal Doppler strain in HCM-patients.28 Additionally, 
reduced septal longitudinal Doppler strain correlated well with increased wall thickness and 
degree of asymmetrical septal hypertrophy. In 2004 strain by speckle tracking 
echocardiography (STE), a more robust and angle independent method using conventional 
two-dimensional (2D) grey-scale imaging, was validated by Amundsen et al in 2006.23 Serri et 
al used this method and compared myocardial function in HCM-patients and normal and 
described reduced segmental and global 2D strain in HCM patients despite normal EF.22 In 
the same paper, in a subgroup analysis of HCM-patients with asymmetrical septal 
hypertrophy, the authors demonstrated that the strain values in the basal septal segments 
were lower than other LV segments.22  
Late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) imaging has become 
the reference standard for noninvasively assessment of myocardial scarring. A substantial 
part of the HCM-patients have fibrosis detected with LGE.29 The distribution of LGE in HCM-
patients does not correspond to coronary arteries, but is mainly located in the mid-wall of 
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the hypertrophic regions and characteristically appears as small punctuate and patchy 
hyperenhancements.29 Case reports of HCM-patients have demonstrated that location of 
myocardial fibrosis post-mortem is similar to that of fibrosis diagnosed by LGE studies,30,31 
but the histological substrate of LGE in HCM-patients is not finally determined. Whether 
gadolinium-contrast accumulates only in areas with replacement fibrosis, or also 
accumulates in areas with interstitial fibrosis, is debated.31  There is an association between 
the presence of LGE and cardiovascular mortality, heart failure death and all-cause death,32 
and LGE is associated with ventricular arrhythmia on Holter monitoring.31,33 However, at this 
time there is still insufficient evidence to support a significant association between the 
extent of LGE and outcome.34-37   
SCD due to ventricular tachyarrhythmias is most common in young asymptomatic patients 
<30 year of age.38 Several deaths in competing athletes have drawn public attention to the 
disease. In a total HCM-population the over-all annual mortality is ≤1%, but high risk groups 
closes up to 6%.39 Implantable cardioverter defibrillator (ICD) is the only effective treatment 
preventing SCD, but prediction of malignant arrhythmias and SCD based on individual 
symptoms and characteristics have been of limited success.40  
It is well established that left ventricular outflow tract (LVOT) obstruction is a major 
determinant of outcome41 and often contributes to the heart failure-related symptoms that 
may occur in HCM.42 One third of the HCM-patients are obstructive with a peak resting LVOT 
gradient ≥30 mmHg (basal obstructive HCM).43 The mechanisms of LVOT obstruction are 
usually related to mitral valve systolic anterior motion (SAM) and basal septal 
hypertrophy.44,45 The level of the obstruction in the LV cavity is related to the SAM contact 
point and the region of the maximal septal hypertrophy. Midcavitary obstruction occurs due 
to midventricular hypertrophy, hypertrophied papillary muscles46 or anomalous papillary 
muscle insertion into the anterior mitral leaflet with the possibility of development of an 
apical aneurysm.47 The LVOT gradient (ΔP) is measured as a peak instantaneous LVOT 
velocity (m/sec) using the simplified Bernoulli formula (ΔP=4V2).  It is important to avoid 
contamination with the Doppler signal from the mitral regurgitation. Another third of the 
HCM-patients have dynamic LVOT obstruction with a resting LVOT gradient <30 mmHg and a 
significant increase of the gradient above 30 mmHg during Valsalva manoeuvre or exercise 
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testing (labile obstructive HCM).43 The final third of the HCM-patients has a LVOT gradient 
<30 mmHg both at rest and with provocation (non-obstructive HCM).  
Figure 4.2. HCM-patients are classified as non-obstructive, labile obstructive and basal 
obstructive due to their resting and/or provocable (Valsalva manoeuvre or exercise induced) 
peak LVOT gradient48. The LVOT gradient (ΔP) is calculated from the peak instantaneous 
LVOT velocity (m/sec) using the simplified Bernoulli formula (ΔP=4V2).  
It has clinical important consequences to distinguish between obstructive and non-
obstructive patients because treatment strategies rely on these. Marked gradients ≥30-50 
mmHg at rest or ≥50 mmHg with provocation, represent the thresholds for septal reduction 
therapy with either surgical myectomy or percutaneous transluminal septal myocardial 
ablation (PTSMA), if symptoms cannot be controlled by medications.5  
Septal reduction therapy is indicated in HCM-patients with severe symptoms despite optimal 
medical therapy.2 The patients have to be basal obstructive or labile obstructive with LVOT 
gradient at rest ≥30-50 mmHg or ≥50 mmHg with physiological provocation, associated with 
SAM of the mitral valve and septal hypertrophy ≥15-16 mm.  
Surgical myectomy was introduced in the 1950s and has been the preferred option to relief 
LVOT obstruction and symptoms at experienced centres with solid short and long term 
results.49-53 Surgical myectomy is done only at selected centres and is therefore less available 
for a substantial part of symptomatic obstructive HCM-patients. Because of comorbidities 
and advanced age, some patients are not optimal candidates for surgery, and in 1995 the 
catheter based procedure PTSMA was introduced.54 Several studies have reported both 
short- and long term outcome of PTSMA (small single-centres studies with 50-138 patients 
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included55-60, large single-centres studies with 312-629 patients included61-63, one meta-
analysis64). In June 2011 an American multi-centre study of long term outcome after PTSMA, 
reporting 9-year mortality, was published.65 There are no randomized trials, only 
observational studies58,66-72 and meta-analyses73-76, comparing the outcomes of PTSMA and 
myectomy. These studies report similar low rates of all-cause mortality and SCD following 
PTSMA and myectomy. However, the rest-gradient after PTSMA tends to be higher than 
after myectomy, and some more patients need a permanent pacemaker after PTSMA due to 
advanced atrioventricular block.73 Most patient develop right bundle branch block after 
PTSMA, and left bundle branch block after myectomy.77 In the latest European guidelines 
from 2014 PTSMA and myectomy are considered equivalent, but myectomy is 
recommended if there are additional lesions requiring surgical intervention (mitral valve 
repair/replacement, papillary muscle intervention, coronary artery by-pass graft surgery or 
aortic valve replacement).5 PTSMA may be less effective in patients with severe hypertrophy 
(≥30 mm) and in patients with extensive scarring on CMR, but systematic data lack.5 Many 
patients prefer the less invasive PTSMA procedure. Studies report non-successful treatment 
of PTSMA in 10-20% of the patients, but there are no established prediction factors 
according to predict successful PTSMA.   
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5. AIMS OF THE THESIS
This thesis is based on two main objectives. First, we wanted to evaluate the relation 
between fibrosis and clinical characteristics in HCM patients. The other main objective was 
to evaluate the effect of PTSMA and factors associated with non-successful PTSMA. 
The aims of the present work were: 
1. To investigate the impact of different types of fibrosis on ventricular arrhythmias
and on myocardial function (Paper I).
2. To compare the ability of two non-invasive imaging methods to detect myocardial
fibrosis (Paper II).
3. To identify patients that do not benefit on PTSMA treatment (Paper III)
4. To analyse the short- and long-term outcome of PTSMA compared to a normal
background population (Paper IV).
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6. PATIENTS AND METHODS 
 6.1. Patient population 
The majority of HCM patients referred to Oslo University Hospital, Department of 
Cardiology, Rikshospitalet are either obstructive considering septal reduction therapy or 
they are referred according to risk stratification considering ICD implantation. Since 2001 
PTSMA has been a part of the treatment options at Department of Cardiology, Oslo 
University Hospital, Rikshospitalet. Septal myectomy was reintroduced as a surgical 
procedure at Department of Cardiothoracic Surgery, Oslo University Hospital, Rikshospitalet 
in 2003. PTSMA has been the first line of treatment. Patients with additional significant 
coronary artery disease (CAD) or heart valvular disease are offered myectomy. If the PTSMA-
procedure had to be stopped due to coronary artery anatomy or the delivery area, the 
patients are offered myectomy.  
Between 2001 and 2009 104 patients with HCM were referred to Oslo University Hospital for 
evaluation for septal reduction therapy and were recruited to this prospective observational 
study (Paper I, II and III, and the Norwegian part of the patients in Paper IV) (Figure 7.1.). 
Eighty-four of the 104 patients were considered to fulfil criteria for septal reduction therapy 
with symptoms (New York Heart Association (NYHA) functional class >2) despite optimal 
medical treatment and a resting LVOT gradient ≥30 mmHg or a provocable LVOT gradient 
≥50 mmHg. The decision of treatment strategy was made after thorough information to the 
patients about the two intervention methods, and after interdisciplinary team-work with 
experienced thoracic surgeons and cardiologists with special interest for HCM-patients. Two 
patients fulfilled the septal reduction therapy criteria, but did not receive septal reduction 
therapy due to co-morbidity in one and the patient`s own desire in the other. Due to limited 
basal septal hypertrophy and a serious LVOT gradient and mitral regurgitation with long 
leaflet and SAM, one patient was operated with mechanical mitral valvular replacement 
without additional myectomy. One patient had had a prior unsuccessful PTSMA in 2002, at 
another heart centre, with persistent symptoms and significant LVOT gradient. The patient 
had a re-do PTSMA in 2004.  Forty-six patients were selected for PTSMA and 34 for 
myectomy. One of the myectomized patients was selected to myectomy based on individual 
preferences. Twenty-three of the myectomy-patients needed combined surgery with either 
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additional coronary artery bypass graft surgery and/or heart valvular surgery. In 5 of the 
patients selected for PTSMA the procedure was stopped due to the coronary anatomy in 2 
patients and due to unsatisfactory delivering area in 3. Four of these patients were operated 
with isolated myectomy, but in one patient myectomy was contraindicated due to co-
morbidity. Three months after the attempt of PTSMA this patient died due to acute 
decompensated heart failure.  
Figure 6.1. Flow chart of the total population of 104 HCM-patients referred to Oslo University 
Hospital primarily considering septal reduction therapy between 2001 and 2009. 
Abbreviations: MVR, mitral valve replacement; PTSMA, percutaneous transseptal myocardial 
ablation; SRT, septal reduction therapy. 
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 6.2. Scandinavian HOCM database 
The Scandinavian HOCM database (www.scand-hocm.org) was established in collaboration 
among heart centres at Copenhagen University Hospital, Rigshospitalet, Denmark, 
Copenhagen University Hospital, Gentofte, Denmark, Karolinska University Hospital, 
Stockholm, Sweden, and Oslo University Hospital, Rikshospitalet, Norway, in 2006. The 
database is defined as a quality register and was built up in collaboration with all the 
participating countries. The register complies with data registry regulations within the 
European Union and in Norway, and was approved by relevant data authorities and 
committees for ethics in medicine. According to the Regional Committee for Medical 
Research Ethics in Norway and the Privacy Policy at Oslo University Hospital, the register at 
Rikshospitalet in Oslo was defined as a combined quality and research register requiring 
written and oral informed consent from the participants. Two participants from the 3 
countries constitute the steering board of the database. 
In Paper IV all PTSMA-treated patients from 1999 to 2010 in the 4 centres were included, of 
which 35 Norwegian patients. The patients were referred from a background population of 
approximately 50% of the Scandinavian population corresponding to 10 million citizens. In 
2007 retrospective data for this study were merged in the database, and since 2007, 
prospective data from new patients and follow-up data have been included. Data retrieved 
from patients’ files, echocardiography reports, and survival registries, were registered at 
baseline and annually during follow-up. Data were extracted from the Scandinavian HOCM 
database on 4th of April 2010. 
All the centres used the same HCM-diagnose definition and the same septal reduction 
therapy criteria, unless the peak resting LVOT gradient which was ≥30 mmHg in Oslo and ≥50 
mmHg in the other centres. The PTSMA procedure and monitoring of the patients after the 
procedure were the same at the 4 centres.   
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 6.3. Genetic testing 
All patients included in this study were tested for mutations in 6 regions encoding cardiac 
sarcomere-proteins.  A total of 86 polymerase chain reaction products together spanning the 
translated exons with flanking intron sequences of the sarcomere genes myosin-binding 
protein C (MYBPC3), β myosin heavy chain (MYH7), regulatory and essential light chains of 
myosin (MYL2 and MYL3), and cardiac troponin T (TNNT2) and I (TNNI3) were subjected to 
DNA sequencing using Version 3.1 of BigDye terminator cycle-sequencing kit and a Genetic 
Analyzer 3730 from Applied Biosystems (Foster City, CA). Pathogenicity of identified 
mutations was assessed by the use of the bioinformatics programs PolyPhen2 
(http://genetics.bwh.harvard.edu/pph2/) and SIFT (http://sift.jcvi.org/). 
 6.4. Exercise test 
A maximal symptom limited exercise test was performed at baseline, and 3 and 12 months 
after septal reduction therapy using an electrically braked bicycle ergometer (Jaeger ER900, 
VIASYS Healthcare GmbH, Hochberg, Germany). A protocol starting at 20 watt with 20 watt 
increase every other minute was chosen and repeated for all patients. Oxygen consumption 
(VO2), CO2 production (VCO2), and ventilation (VE) were measured in 38% (39/104, 2007 - 
2009) of the patients on a breath-to-breath basis (MVmax 229, VIASYS Healthcare GmbH, 
Germany). Heart rate and electrocardiogram (ECG) were continuously recorded, and blood 
pressure was recorded at baseline, at every step, and every minute after ended exercise. 
Peak VO2 and respiratory exchange ratio (RER) were registrated at the end of the test.   
 6.5. Holter monitoring 
Forty-eight hours ECG monitoring with 5 electrodes (Medilog, ScanMed AS) was performed 
prior to and 3 and 12 months after the septal reduction therapy. Type of rhythm, episodes of 
bradycardia, and supraventricular (atrial fibrillation and other forms of supraventricular 
arrhythmias) and ventricular arrhythmias (non-sustained ventricular tachycardia (NSVT) and 
ventricular tachycardia (VT)) were registered.   
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6.6. Risk stratification and definition of ventricular arrhythmia 
Risk stratification in order to prevent SCD and evaluation of indication of ICD were 
performed prior to, and 3 and 12 months after septal reduction therapy. According to 
guidelines from 2003 for risk stratification, patients with survived heart arrest or 
documented sustained VT were offered a secondary preventive ICD.3 NSVT was defined as 3 
or more ventricular complexes with heart rate ≥120 and duration <30 seconds. If two or 
more of the following risk factors were available, implantation of ICD was evaluated: (1) 
family history of premature SCD, (2) recent unexplained syncope (suspected arrhythmogenic 
syncope and/or syncope during exercise), (3) documented NSVT, (4) LV hypertrophy ≥30 
mm, (5) abnormal blood pressure response during exercise testing. Premature SCD in the 
family was defined as sudden unexpected death without any known heart disease and/or 
HCM-related sudden death in first- and/or second degree relatives, and age < 40 year. In 
Paper I and II ventricular arrhythmia was defined by ≥1 of the following criteria: (1) prior 
cardiac arrest with documented ventricular arrhythmias, (2) documented NSVT at Holter 
monitoring, (3) unexplained syncope. 
 6.7. Echocardiography 
Transthoracic echocardiography was performed at baseline, and 3 and 12 months after 
septal reduction therapy, using a commercially available digital ultrasound scanner (Vivid 7 
with the M3S transducer, GE Vingmed Ultrasound, Horten, Norway). Images were obtained 
in two parasternal and three standard apical views and the recordings and analyses were 
performed according to standards.78 In Paper I and II maximal wall thickness (MWT) and 
septum-posterior wall ratio were assessed from parasternal short-axis plane at the level of 
the papillary muscle. Additionally, in Paper III, maximal basal septal hypertrophy (end-
diastolic interventricular septal dimension (IVSd)) was evaluated in 2D greyscale images from 
parasternal long-axis plane. In Paper IV measurements of IVSd was performed either with 2D 
greyscale images or M-mode from parasternal long-axis view.  
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Figure 6.2. End-diastolic interventricular septal dimension (IVSd)) was evaluated in two-
dimensional greyscale images from parasternal long-axis plane (left). Maximal wall thickness 
(MWT) and septum-posterior wall ratio were assessed from parasternal short-axis plane at 
the level of the papillary muscle (right). 
To measure the extent of LV hypertrophy we used Spirito-Maron index and Wigle’s score 
(Paper II).79,80 Peak resting LVOT gradient was measured by continuous wave Doppler. When 
resting LVOT gradient was <30 mmHg exercise induced LVOT gradient was measured by 
ergometric stress-echocardiography. Ergometric stress-echocardiography was done in a 
subset of 63 patients (61%) with a semi-recumbent exercise bike (Ergoline) in a tilted 
position (Figure 7.2.). A protocol starting at 20 watt with 20 watt increase every second 
minute was chosen and repeated for all patients. During the test continuous rhythm 
registration (12-lead ECG) and blood pressure measurements every second minutes were 
done. Peak LVOT gradient was measured at rest, after 4-6 minutes exercise, and at maximal 
exercise. Peak exercise induced LVOT gradient was defined as maximal LVOT gradient 
measured during exercise.  
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Figure 6.3. The semi-recumbent exercise bike (Ergoline) used for ergometric stress 
echocardiography. 
2D strain by STE was performed in the three standard image planes from the apex. The 
endocardial contour was traced on an end-diastolic frame, and the software automatically 
tracked the contour, and with of region of interest (ROI) was adjusted to fit the average of 
the myocardial thickness. If segments were automatically excluded by the software, the 
width of ROI and/or the endocardial contour were manually adjusted to achieve an optimal 
speckle tracking. Global longitudinal strain was defined as an average of peak systolic strain 
in a 16-segments model. Septal longitudinal strain was defined as an average of peak systolic 
strain of basal- and mid-septal segments from the apical 4-chamber view (Paper I: 2-
segments septal strain) and from apical long-axis view and apical 4-chamber view (Paper II: 
4-segments septal strain).
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Figure 6.4. Sixteen-segments model of longitudinal strain by speckle tracking 
echocardiography. Septal longitudinal strain was defined as an average of peak systolic 
strain of basal- and mid-septal segments from the apical longaxis (A) and 4-chamber view 
(C). A shows apical longaxis view, B apical 2-chamber view, and C apical 4-chamber view.   
Global circumferential strain was obtained from short axis view at the papillary muscle level, 
averaging peak systolic strain from six segments. Septal circumferential strain was defined as 
an average of peak systolic strain from two septal segments. In a subset of 18 patients 
(Paper II) global longitudinal strain was additionally evaluated with tissue Doppler imaging-
derived strain. 
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Figure 6.5. Six segments model of circumferential strain by speckle tracking 
echocardiography. Septal circumferential strain was defined as an average of the 
anteroseptal and septal segments from the parasternal shortaxis-view. 
 
 6.8. Cardiac magnetic resonance  
Cardiac magnetic resonance (CMR) was performed at baseline in 77 of the 104 patients. In 
69 patients late LGE-CMR was available. CMR was performed using a 1.5 tesla scanner 
(Siemens, Erlangen, Germany) and a phased array body coil. Using an electro cardiogram-
triggered segmented balanced gradient echo technique, breath-hold long axis and short axis 
cine images were acquired. After 10-20 minutes intravenous injection of 0.2 mmol/kg 
gadopentetate dimeglumine were injected. The LGE images were obtained with multiple 
short axis slices covering the entire LV with a slice thickness of 7 mm and an interslice gap of 
3 mm. With an inversion time of 210 – 260 msec a breath-hold segmented magnetization-
prepared turbo gradient echo sequence was used.  
 
Figure 6.6. LGE-CMR short-axis image of a patient with obstructive hypertrophic 
cardiomyopathy with LGE present in the basal anteroseptal (upper area) and inferoseptal 
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segments(lower area). Adapted by permission from BMJ Publishing Group Limited (Almaas et 
al, Heart 2014;100:631-638).81 
EF was calculated using end-diastolic volumes and end-systolic volumes. The extent of LGE 
was quantified in a subset of 25 myectomized patients, by a visual appreciation using a 17-
segments model.82 For each segment, the areas of the LGE and the area of the entire 
myocardium were manually drawn. The amount of LGE was calculated as percentage of the 
actual segment. Global LGE was defined as the percentage LGE of LV. Septal LGE was defined 
as the percentage LGE of the basal and mid antero- and inferoseptal segments.83 The LV 
mass was calculated by adding the areas of all 17 segments and multiplying by 1.04 g/cm3.84 
All the CMR analyses were performed by an experienced radiologist (HJS) blinded to all 
clinical data. 
 
 
Figure 6.7. An illustration of the 17 segments CMR model. The percentage LGE in the basal 
and mid antero- and  inferoseptal segments was defined as septal LGE. 
  
6.9. PTSMA 
In the first 29 patients both catheter measured and transthoracic echocardiographic LVOT 
gradient was determined prior to the procedure, and in the last 18 patients only 
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echocardiographic measured LVOT gradient was used. The left main coronary artery was 
intubated and visualized, after which the first septal branch was probed. Then, an over the 
wire angioplasty balloon catheter was placed in the proximal part of the septal branch. After 
the balloon was inflated to a pressure of 8 bars, an injection of contrast medium through the 
balloon central lumen was done. Simultaneously transthoracic echocardiography was used 
to confirm the delivery area to only the target myocardium, which was defined as the septal 
region corresponding with SAM-contact point and peak LVOT gradient. If the target 
myocardium was not reached, a more distal branch or the second septal branch was tried.  
In some few patients the contrast enhanced other regions (papillary muscles) and the 
procedure had to be stopped. When the contrast enhancement confirmed delivery area to 
the target myocardium, about 1-2.5 ml of 96% alcohol was injected. Immediately after the 
alcohol-injection the LVOT gradient, measured by echocardiography, was reduced. The 
balloon catheter was deflated after 10 minutes. If the LVOT gradient was not reduced to <16 
mmHg, an additionally smaller dosage of alcohol (0.5 – 1 ml) was injected in a more distal 
septal branch or in the second septal branch after controlling the delivery area. After the 
PTSMA-procedure the patients were carried out in the intensive care unit for 24 hours for 
ECG monitoring and determination of creatine kinase (CK), creatine kinase muscle-brain 
fraction (CK-MB), and Troponin T values 6 hours after the procedure and the following 
morning, followed by daily ECG check-ups including evaluation of development of bundle 
branch block and measurements of PQ-time according to development of atrioventricular 
block. The patients were transferred to the cardiologic ward for 3-5 days with continued ECG 
monitoring, unless they had developed atrioventricular block in need of pacing. The 
temporary pacing wire inserted prior to the ablation was left there for at least 48 hours. A 
transthoracic echocardiographic examination was done before discharge 
 
 6.10. Myectomy 
The interventricular septum was exposed through an aortic incision, protecting the aortic 
leaflets. After visual inspection and digital exploration the myocardial resection was started 
below the right coronary cusp moving distally and leftwards. The dissection proceeded distal 
to the mitral valve contact with the septum, taking care to remove fibrous tissue and 
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aberrant muscle bundles towards the apex. Valve function, extent of resection and relief of 
LVOT obstruction as well as unexpected findings was evaluated by transoesophaegal 
echocardiography, and guided the surgeon whether to resume surgery or complete the 
operation. 
 
Figure 6.8. An illustration of the basal septal area resected during myectomy. Ao, aorta; IVS, 
interventricular septum; LA, left atrium; LV, left ventricle.  
 
 
 6.11. Histologic examination of the operation specimens 
The operation specimens were fixed in 10% formalin, paraffin-embedded and sectioned for 
light microscopy. Two staining methods were used for light microscopy; hematoxylin-eosin-
saffron and acid fucsin orange-G (AFOG). The last method was used to highlight connective 
tissue. To exclude storage disease a small proportion of each specimen was fixed in 
glutaraldehyd, embedded in epon and processed for electron microscopy.  
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Figure 6.9. Hematoxylin-eosin-saffron-stained sections form myectomy specimens. A: 
Myocyte disarray. B: Myocyte hypertrophy without disarray. Reprinted with permission form 
European Cardiology 2010;6:88-91.85 
We classified the fibrosis as interstitial, replacement, perivascular or subendocardial.14 
Confluent fibrosis substituting the myocytes were classified as replacement fibrosis, and thin 
strands of fibrous tissue encircling the myocytes were classified as interstitial fibrosis. 
Perivascular fibrosis and myocyte disarray were assessed as being present or not. 
Subendocardial fibrosis was excluded from the analyses. 
 
 
Figure 6.10. AFOG-stained sections from myectomy specimens. Collagen fibrils (fibrosis) are 
staining blue, nucleus black, erythrocytes and cytoplasm pink-orange, elastic fibrils pale pink 
or unstained, and protein deposits red.  A: Interstitial fibrosis. B: Replacement fibrosis. C: 
Perivascular fibrosis. D: Subendocardal fibrosis. Reprinted with permission form European 
Cardiology 2010;6:88-91.85 
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 Interstitial and replacement type of fibrosis were quantified in AFOG-stained sections by 
two observers (EHS and HS) simultaneously. The observers were blinded for clinical data and 
outcome. They made a visual estimate of the percentage area affected by interstitial and 
replacement fibrosis of the total specimen. Total amount of fibrosis was an addition of 
interstitial and replacement fibrosis. After 12 weeks a repeated blinded quantification of 
replacement fibrosis was performed.  
 
 6.12. Statistical analysis 
Unpaired Student’s t-test was used to compare normally distributed continuous data 
presented as mean ± standard deviation (SD), and Mann-Whitney U test to compare non-
normally distributed data presented as medians (25%, 75% percentiles). Pearson Chi Square 
or Fischer’s Exact test were used for comparisons of proportions. Two-sided p-values <0.05 
were considered statistically significant. Reproducibility was expressed by intraclass 
correlation coefficient in Paper I and II. All statistical analyses were performed with SPSS 
IBM, New York (version 18 in Paper I and II, and version 21 in Paper III),  
 
In Paper I univariate linear regression analyses were used to identify explanatory variables of 
reduced septal longitudinal strain. In the total population (n=63) and in the histology 
population (n=24) univariable logistic regression analyses were used to identify predictors of 
arrhythmic events. In the total population multivariable analysis was performed including 
significant variables (p<0.05) from the univariable analyses. Receiver operating characteristic 
(ROC) analyses were used to assess the ability of global and septal longitudinal strain and 
amount of histological fibrosis to discriminate patients with ventricular arrhythmias.  
 
In Paper II non-parametric correlation test (Spearman’s rho) was used to analyse the relation 
of %area of histological fibrosis, %LGE, and echocardiographic strain. To identify predictors 
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of histological fibrosis ≥15% (50% percentile) univariable logistic regression analyses were 
performed. Modifying factors as CAD, MWT, and peak LVOTG, were included in the 
multivariable logistic regression analysis.  
 
In Paper IV “baseline” refers to pre-PTSMA data and “most recent follow-up” to the most 
recently available data after PTSMA. When normally distributed, data was presented as 
mean±SD and when non-normally distributed as median (interquartile range). Proportions 
were presented as percentages (%). Student’s t-test or Wilcoxons Rank Sum tests were used 
for unpaired comparisons of the data, depending on normally or non-normally 
distribution.Student’s t-test was performed for paired comparisons of continuous variables. 
Proportionswere compared with Chi-square test or Fishers exact test when unpaired, and 
McNemar testwhen paired. In the survival analyses death of all causes was considered an 
event. KaplanMeier estimates of survival were calculated, and time-to-event curves were 
compared performing Log Rank test. Univariate Cox regression model was performed to 
predict death of all causes, and predictors showing association (p≤0.1) with decreased 
survival entered a multivariate Cox regression model. All statistical analyses were performed 
with SAS® statistical software package version 9.1. 
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7. SUMMARY OF RESULTS 
7.1. Paper I  
In this study 63 HCM-patients (mean age 57±13 years) were examined by strain by STE prior 
to septal reduction therapy with either PTSMA (n=37) or basal septal myectomy (n=26). 
Fifteen patients (24%) had experienced ventricular arrhythmias defined as documented VT 
or arrhythmogenic suspected syncope. Patients with ventricular arrhythmias had 
significantly higher MWT, and reduced global and septal longitudinal strain compared to 
those without ventricular arrhythmias. By univariate linear regression analyses, ventricular 
arrhythmias (R2=0.12, p=0.006), MWT (R2=0.28, p<0.001), and the presence of a sarcomere 
mutation (R2=0.10, p=0.01) were significantly associated with reduced septal longitudinal 
strain. In the multiple regression analysis MWT was independently associated with reduced 
septal longitudinal strain (p=0.005). (Reduced septal longitudinal strain, increased MWT, and 
genotype-positive status significantly predicted ventricular arrhythmias. In the multivariable 
analyses septal longitudinal strain was an independent predictor of ventricular arrhythmias. 
Operation specimens were available in 24 of the myectomized patients (histology 
population). Six of these patients (25%) experienced ventricular arrhythmias. In the histology 
population the patients with ventricular arrhythmias had a greater extent of total fibrosis 
(47(30, 71)% vs. 10(6, 15)%, p=0.001), interstitial (44(23, 61)% vs. 7(2, 12)%, p=0.001) and 
replacement fibrosis (7(3, 14)% vs. 3(1, 3)%, p=0.02) compared to the patients without 
ventricular arrhythmias. There was a linear association between septal longitudinal strain 
and percentage area of total (R2=0.31, p=0.006) and interstitial (R2=36, p=0.003), but not 
with replacement fibrosis (R2=0.03, p=0.43). Univariable logistic regression analysis of septal 
strain, total, interstitial and replacement fibrosis, showed that reduced septal longitudinal 
strain and increased amount of total and interstitial fibrosis significantly predicted 
ventricular arrhythmias.  
These results suggest that total amount of fibrosis is associated with ventricular arrhythmias 
in obstructive HCM patients. Interstitial fibrosis was more important compared with 
replacement fibrosis in arrhythmogenesis, and was related to reduced septal myocardial 
function. These findings suggest that interstitial fibrosis may play an important role as the 
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arrhythmogenic substrate, and that strain echocardiography might be useful in risk 
assessment.  
 
7.2. Paper II 
In this study the abilities of LGE and strain echocardiography to detect type and extent of 
myocardial fibrosis in 32 obstructive HCM-patients (age 60±10 years) undergoing septal 
myectomy were assessed. The percentages of total, interstitial and replacement fibrosis 
were 15(7, 31)%, 11(5, 24)%, and 3(1, 6)%, respectively. LGE was present in 13 out of 21 
patients (62%), and these patients had 9(2, 10)% septal LGE. There were no significant 
differences in echocardiographic and histological parameters between the patients with and 
without septal LGE. No correlations were found between percentage septal LGE and total, 
interstitial, or replacement fibrosis. There was a linear correlation between septal 
longitudinal strain and total and interstitial fibrosis, but not with replacement fibrosis. To 
predict histological fibrosis ≥15% (median value)  the following parameters were used: age at 
intervention, sex, additional diseases, CAD, HT, MWT, peak LVOT gradient, EF, global 
longitudinal strain, septal longitudinal strain, global circumferential strain, and septal 
circumferential strain. Septal longitudinal strain predicted histological fibrosis ≥15% in both 
univariable analyses and in the multivariable model.  
 
Eight patients (25%) experienced ventricular arrhythmias. These patients had a higher 
amount of total and interstitial fibrosis, and a lower septal longitudinal strain compared to 
the patients without arrhythmias (n=24). In univariable logistic regression analyses and in 
the multivariable model, septal longitudinal strain and interstitial fibrosis predicted 
ventricular arrhythmias significantly. LGE did not predict ventricular arrhythmias. No 
significant differences were demonstrated between patients with (n=4) and without (n=9) 
ventricular arrhythmias with respect to percentage global and septal LGE. 
Thus, in myectomised HCM-patients the extent of total fibrosis correlated with preoperative 
reduced septal strain, but not with the amount of septal LGE. Echocardiographic strain might 
add valuable information in HCM-patients. 
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7.3. Paper III 
In this study we evaluated whether pre-procedural parameters were associated with non-
successful PTSMA. Echocardiographic and clinical examinations were performed before 
procedure and one year after. At one year follow-up we used three definitions of successful 
intervention. Symptomatic success was defined as a reduction of ≥1 NYHA functional class. 
Hemodynamic success was defined as rest LVOT gradient <30 mmHg or ≥50% reduction of 
exercised induced LVOT gradient. Combined symptomatic and hemodynamic success was 
defined as a combination of symptomatic and hemodynamic success. 
Forty obstructive HCM-patients (age 56±14 years) treated with PTSMA were enrolled. Two 
patients died, two patients were lost to follow-up, and one labile obstructive patient was not 
evaluated by ergometric stress-echocardiography at one year follow up. Thus, 35 patients 
were evaluated one year after PTSMA. 
One–year survival was 95%, and mean improvement of NYHA functional class 1.0±0.7. The 
reduction of peak LVOT gradient was 37±24 mmHg. Eight out of 35 patients (23%) had 
symptomatic non-successful PTSMA, 9 out of 35(26%) had hemodynamic non-successful 
PTSMA, and 12 out of 35 (34%) had combined symptomatic and hemodynamic non-
successful PTSMA. Non-successful PTSMA (symptomatic, hemodynamic, and combined 
symptomatic and hemodynamic) was associated with younger age at intervention and a 
higher residual LVOT gradient at follow-up than successful PTSMA (p<0.01 for all the 
comparisons). Patients with non-successful hemodynamic response to PTSMA had higher 
transmitral E/A-ratio (1.66±0.91 vs. 1.13±0.38, p=0.03) and lower E-wave transmitral 
deceleration time (201±46 msec vs. 263±76 msec, p=0.04) at baseline compared to 
hemodynamic successful PTSMA. 
 Using all the three definitions of successful PTSMA there were no differences in pre-
procedural peak LVOT gradient, in volume alcohol injected during the procedure and of 
infarction size evaluated with maximum CKMB when comparing successful and non-
successful PTSMA.  
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Thus, patients with non-successful hemodynamic response of PTSMA had pre-procedural 
worse diastolic dysfunction than the patients with successful PTSMA. Patients with non-
successful PTSMA (symptomatic, hemodynamic and combined symptomatic and 
hemodynamic) were associated with younger age at intervention. 
 
7.4. Paper IV 
In this international multi-centre study we evaluated long-term outcome after PTSMA in 279 
obstructive HCM-patients (mean age 59±14 years) at four Scandinavian high-volume PCI-
centres/moderate-volume PTSMA-centres. Long-term outcome of 313 PTSMA procedures 
were reported. Mean time of follow-up were 2.9±2.6 years. 
The resting peak LVOT gradient was reduced from 58(34-89) mmHg at baseline to 12(8-24) 
mmHg at one year follow-up and to 12(8-21) mmHg (p<0.001) at most recent follow-up 
(2.9±2.6 years after first PTSMA). The proportion of patients in NYHA functional class III/IV 
decreased from 94% at baseline to 21% (p<0.001) at one-year follow-up and to 21% 
(p<0.001) at most recent follow-up.  
88% of patients achieved symptomatic improvement defined as decreased NYHA- or CCS-
class or disappearance of syncope at last follow-up. Two years after the procedure 14% of 
the patients were treated with a re-do septal reduction therapy (26 PTSMA, 6 myectomy). 
In-hospital mortality was 0.3%, and 30-day mortality was 0.6%. Twenty percent of the 230 
patients with no permanent pacemaker or ICD prior to PTSMA-procedure, had a permanent 
pacemaker implanted after PTSMA.  
Median observational time used in the survival analyses was 3.7 years (IQR, 1.4 to 6.3 years). 
Overall mortality rate was 3% per year.  The 1-, 5-, and 10-year survival rates after PTSMA 
were 97%, 87%,  and 67%, respectively, compared to 98%, 90%, and 78% in the age- and sex-
matched background population (p=0.06). Patients aged <60 years (48±9 years, n=141) had 
1-, 5-, and 10-year survival rates of 99%, 94%, and 88% compared to 100%, 97%, and 93% 
(p=0.12) in the age- and sex-matched background population. In patients aged ≥60 years 
(70±7 years, n=138) the 1-, 5- and 10-year survival rates were 95% , 79% , and 46% 
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compared to 97%, 83%, and 63% (p=0.09) in the age- and sex-matched background 
population. At most recent follow-up 11% had an ICD. Age at baseline, sex, chronic 
obstructive pulmonary disease, and sum of arrhythmic events during in-hospital monitoring 
showed p-values ≤1 in univariable cox regression analyses and were associated with reduced 
survival. In a multivariable model only age at baseline showed significant association to 
survival (HR, 1.07; 95% CI, 1.03 to 1.1; p=0.001).  
Thus, in this multicentre study, the in-hospital morality after PTSMA was low. The 
symptomatic and hemodynamic effects were sustained. The 10-year survival rate was not 
significantly different from that in a gender- -and age-matched background population.  
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8. DISCUSSION 
HCM is the most prevalent genetic cardiac disease and affects many patients. The disease-
spectrum is broad, ranging from non-discovered symptom-free patients to severe 
cardiomyopathy and sudden death. Selecting the right patient to the right treatment, 
prediction of treatment-response, and identification of patients at risk are crucial. In this 
thesis we have examined several facets of this topic. In Paper I and Paper II we 
demonstrated that reduced longitudinal septal strain correlated with ventricular 
arrhythmias. As reduced strain also was interrelated with increased fibrosis this may provide 
an explanation for this association.  Septal reduction therapy has a central role in 
management of HCM, but the role of myectomy and PTSMA has not been finally 
determined. In paper IV we demonstrated that PTSMA may be performed with satisfactorily 
results. The results in Paper III indicate that younger patients should be offered myectomy as 
these patients are less likely to get good results from PTSMA. Young age at the time of 
symptom debut may reflect a more aggressive disease. In line with this we found that 
genotype positive patients were younger at symptom onset and at intervention, and had a 
higher frequency of ventricular arrhythmias (Paper I). Furthermore, patients with non-
successful PTSMA had a worse pre-procedural diastolic dysfunction. Thus pre-procedural 
assessment is important for selection of the patients to the right treatment.   
 
8.1. The HCM population - one diagnosis - several diseases?  
The European guidelines from 2014 use a purely morphological disease definition of HCM 
with the possibility of a number of aetiologies: “HCM is defined by the presence of increased 
LV wall thickness that is not solely explained by abnormal loading conditions.”  This means 
that the definition of HCM include patients with and without sarcomere-mutations, and 
patients with deposition (e.g. amyloidosis) and metabolic (e.g. Anderson-Fabry) diseases. 
Although these patients meet the diagnosis requirements according to LV wall thickness and 
loading conditions, the underlying pathophysiology could be quite different. The variation in 
the aetiological background included in this broad definition may translate into subgroup 
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differences in risk factors and therapy outcome within the same disease.  Thus the clinicians 
have to be conscious about what kind of HCM-population they are dealing with.  
Initially only the PTSMA-treated patients were included in this study. From 2005 all the HCM-
patients referred to Rikshospitalet considering septal reduction therapy were included. 
Patients who were myectomized before this time were retrospectively included. These 
factors influence on the composition of the HCM-population in this study. Thus in the first 
years primarily obstructive PTSMA- and myectomy-treated patients were included. From 
2005 there is a more mixed population of obstructive and non-obstructive HCM-patients. In 
the final population of 104 patients, 84 (81%) are obstructive. This does not reflect a general 
HCM-population, and for this reason, we have concentrated on the obstructive patients 
(n=84). Primarily 41 patients were treated with PTSMA, and 38 with myectomy (15 isolated 
myectomy, and 23 with combined surgery). Fifty-five percent of the patients (46/84) had 
additional CAD and/or HT and/or other additional diseases, 31% (25/81) of the patients 
tested for a HCM related mutation was genotype positive (unpublished results). Due to 
different research questions and hypotheses different subgroups of the total population of 
84 patients with obstructive HCM are investigated in Paper I, II and III. Paper I contains 63 
patients accepted for PTSMA or myectomy, Paper II includes 32 myectomized patients, and 
Paper III and IV 40 and 279 PTSMA-treated patients, respectively. Due to the intervention-
selection-criteria at Oslo University Hospital, Rikshospitalet, the population treated with 
myectomy contained markedly more patients with additional cardiovascular diseases than 
the PTSMA population. In Paper I 46% (29/63) had additional CAD and/or HT and 38% 
(24/63) were genotype positive. In Paper II 72 % (23/32) had additional diseases with CAD, 
and/or myocardial infarction, and/or HT, and/or diabetes mellitus without organ 
complication, and/or other diseases, and only 13% (4/32) were genotype positive. In Paper 
III 3% had additional CAD, 35% HT, and 45% were genotype positive. 
HCM is a common cardiovascular disease, and in clinical practice a substantial part of the 
HCM-patients have common additional diseases as CAD and HT. In many HCM-studies 
patients with additional diseases are excluded. The reason for limiting investigations to a 
narrowly-defined homogenous HCM-population is to address the pathophysiological 
changes directly related to the sarcomere-disease. However, HCM-patients with additional 
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diseases constitute an important part of the HCM population. Consequently, one must take 
the reservation that results derived from studies where HCM patients with additional 
diseases are excluded cannot be extrapolated to the total HCM-population where additional 
cardiovascular diseases are common. We did not want to exclude patients with common 
additional diseases. Our studies are performed on HCM-populations that include patients 
with additional CAD and HT to reflect the populations that we face in clinical practice.  
There are some differences between the studies in this thesis with respect to inclusion of 
patients with CAD and myocardial infarction. In Paper I all the patients with CAD and 
myocardial infarction were excluded (n=4), but in Paper II only patients with CAD and 
myocardial infarction in the basal septal region were excluded (n=0). Consequently, 4 
patients with myocardial infarction in Paper II were not excluded. Both in Paper I and II 
patients with CAD without myocardial infarction were not excluded. With respect to 
ventricular arrhythmias, these differences did not influence on septal myocardial function 
and the importance of interstitial type of fibrosis.  
To get more knowledge about the effect of an isolated sarcomere-disease and how the 
disease presentation and development are influenced by additional cardiovascular disease, a 
population with pure sarcomere-disease and a population with sarcomere-disease and 
additional cardiovascular disease had to be compared. Another factor that has not been 
studied in this thesis is whether the HCM disease in itself influences that development of 
CAD and whether CAD influences the progression of a HCM disease. The frequency of CAD in 
the obstructive HCM group exceeds the rate found in an age-matched population by far. 
Whether this reflects that the HCM disease increases the risk of CAD or whether this is 
merely a reflection of the selection of the patient groups is undetermined. The lower 
incidence of CAD in the genotype positive HCM population may be explained (at least partly) 
that these patients are younger at the time of intervention. The interrelationship between 
CAD and HCM disease should be studied further.   
In addition to the rate of obstructive HCM patients and the number of patients with 
additional diseases other factors as age at debut of symptoms and genotype status are 
important characteristics. In Paper I we found that the genotype positive patients were 
younger at symptom onset and at intervention, and had a higher frequency of ventricular 
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arrhythmias. Additionally, in Paper III we found that younger patients had less favourable 
effects of PTSMA compared to older patients. This may reflect that the disease progression is 
different according to age at symptom debut and genotype status.86,87  
More than 1400 mutations in 11 or more sarcomere-genes are known to definitively cause 
HCM. Of the genotype positive patients, about 70% are found to have mutations (of either 
definitive or uncertain pathogenicity) in the most common genes, beta myosin heavy chain 
(MYH7) and myosin binding protein C (MYBPC3), while other genes including troponin T 
(TNNT), troponin I (TNNI), alpha tropomyosin, actin, regulatory light chain, and essential light 
chain, each account for a small proportion of the patients (1-5%).6,8 In 1990 the first 
description of a specific HCM mutation (beta myosin heavy chain) was reported88, but the 
molecular mechanisms by which HCM-associated mutations cause the disease remain 
unclear and controversial.7 Initially, impaired myofibrillar contractile function was suggested 
to be the most important mechanism accounting for compensatory hypertrophy and 
diastolic dysfunction, but the altered contractility caused by various sarcomeric gene 
mutations is not consistently found. A variety of functional defects, including altered calcium 
cycling and sarcomeric calcium sensitivity, increased fibrosis, disturbed biomechanical stress 
sensing and impaired energy homeostasis have been revealed.7,89 In the past some HCM 
genes and variants have been reported to convey more severe disease than others, but on 
the basis of large cohorts of genetic tested unrelated HCM-patients there are now consensus 
that a specific HCM mutation cannot predict clinical outcome.5,6 Anyway, irrespective of a 
defined HCM-mutation, genotype positive HCM-patients have increased risk of adverse 
events compared to genotype negative HCM-patients.86,87 Up to 5% of the patients carry at 
least two independent mutations (compound or double heterozygous). Triple gene 
mutations in sarcomeric proteins has been reported with an incidence of 0.8%.7 Double and 
triple mutations are associated with early onset and a severe phenotype. In line with earlier 
published studies, our results indicate that genotype positive HCM-patients (sarcomere-
mutations) have a poorer prognosis compared to genotype negative patients.86,87 The 
composition of the patient populations should be carefully considered when different 
studies are compared. 
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 8.2. Fibrosis  
Paper I (n=24) and II (n=32) included overlapping, but slightly different, populations as 
patients with additional diseases suspected to produce hypertrophy were excluded in paper 
I, but not in paper II. However, the presence of total (100% vs 97%), interstitial (100% vs 
94%),  and  replacement fibrosis (100% vs  97.%), and the median amount of total (14% and 
15%), interstitial (10% vs 11%) and replacement fibrosis  (3% vs 3%)  were not different in 
the two studies. Moravsky et al have published similar levels of fibrosis in HCM patients with 
mean amount of total fibrosis (16%), interstitial fibrosis (14%) and replacement fibrosis 
(2%)90  In Paper I and II we used AFOG as a myocardial fibrosis staining method. AFOG has 
been the preferred fibrosis-staining method at our laboratory due to visibility and contrast 
to other co-stains used. Collagen fibrils are staining blue, nucleus black, erythrocytes and 
cytoplasm pink-orange, elastic fibrils pale pink or unstained, and protein deposits red. 
Various staining methods for assessment of fibrosis in HCM patients have been used, 
including Picro Sirius21 and different trichrome methods.90 In the recent years Picro Sirius has 
been the most frequently used fibrosis staining method.91 None of the methods are specific 
for collagen as other connective tissue components are also stained. Studies comparing the 
methods are scarce. Despite different staining methods both Moravsky et al and Shirani et al 
reported fibrosis in HCM patients at the same level as we did. The latter study included 
however younger HCM patients so the populations are different. Nevertheless we have no 
indications that these differences in staining methods constitute major differences in the 
interpretation of the level of fibrosis.   
Studies of different cardiac diseases have shown remodelling of the extracellular matrix 
components resulting in enhanced stiffness of the myocardium and diastolic and systolic 
dysfunction as well as increased electrical instability.92-98  Ho et al examined 77 genotype 
positive HCM-patients, 38 with overt HCM and 39 without LV hypertrophy (genotype 
positive/phenotype negative) and 30 controls, with serum biomarkers of collagen 
metabolism.95 All the 77 patients had increased amount of serum biomarkers indicating 
increased myocardial collagen synthesis. The fact that all the 39 genotype positive patients 
without LV hypertrophy had increased levels of serum biomarker for collagen synthesis 
indicated that myocardial interstitial fibrosis was an early disease manifestation in patients 
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with HCM. These findings correspond well with Shirani et al who examined 16 previously 
asymptomatic children and young adults with HCM who died suddenly, and found increased 
amount of  and changed structure of microscopic analysed interstitial matrix collagen 
(interstitial fibrosis) compared to controls . None of these patients had myocardial 
replacement fibrosis. Our results in Paper I and II indicate the same, that increased amount 
of both total and interstitial fibrosis is associated with ventricular arrhythmias. The 
association between myocardial fibrosis and arrhythmias make non-invasive assessment 
methods assessing HCM related fibrosis, possible candidates to predict arrhythmias.  
 
8.3. Arrhythmia, LGE and strain 
Prediction of risk for malignant arrhythmias and SCD is important in the care of HCM 
patients. In the papers included in the thesis we found that 24% (Paper I), 25% (Paper II) and 
23% (Paper III) of the obstructive HCM patients were diagnosed with ventricular arrhythmias 
(including arrhythmia suspect syncope) before septal reduction therapy. These figures are in 
line with other studies.31,33,37,99,100 Patients with one or several of the traditionally 5 risk 
markers have increased risk of SCD.2-4 Unfortunately, these 5 risk markers have low positive 
predictive value, and many of the patients who have an ICD implanted never experience ICD-
discharge. On the contrary, the absences of these 5 risk factors has a negative predictive 
value of >95% for malignant arrhythmias. In 2014 a novel risk prediction model, using 7 
predictors (age, maximum LV wall thickness, LA size, max LVOT gradient, family history of 
SCD, NSVT and unexplained syncope), for SCD in HCM-patients was described.101 The risk 
prediction model make a individualize 5-years low (<4%), intermediate (≥4% and <6%) or 
high (≥6%) risk estimate for the probability of SCD.3,101 However, the effort to improve the 
prediction models continuous in order to pick the right patients for ICD and several other 
factors such as myocardial fibrosis determined by LGE-CMR, LV apical aneurysm and the 
inheritance of multiple sarcomere protein gene mutations have been suggested.2,5 LGE-CMR 
has been associated with ventricular arrhythmias and development to heart failure and end-
stage disease.31,33,102 Available data is currently not considered sufficient for LGE to be 
judged as an independent risk marker for adverse prognosis and SCD in HCM in addition to 
or replacing the other traditional risk factors.5,35 In Paper II we did not find any significant 
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differences in amount of global or septal LGE between patients with or without ventricular 
arrhythmias. However, this may be due to the relatively low number of patients. In a recent 
published study of 1293 HCM-patients Chan et al showed for the first time that increased 
extent of LGE was associated with an increased risk of SCD.35 They demonstrated a 2-fold 
increase in SCD risk in those patients otherwise considered to be at lower risk. However, it 
has to be mentioned that McKenna and Nagueh pointed out that 16 of the 20 patients (80%) 
who died suddenly or experienced a cardiac arrest had LGE ≤5%.103 This indicates that while 
there is an association between LGE and arrhythmias this tool is not yet sensitive enough to 
predict ventricular arrhythmias. One factor that may explain this is the fact that the 
histological substrate representing LGE is not finally characterized, and there is an ongoing 
discussion whether the interstitial fibrosis can be detected with the LGE-method at all.20 
Gadolinium is an extracellular agent accumulating in areas with interstitial expansion due to 
myocardial fibrosis, oedema or infiltration.104 In animal models delayed enhancement 
corresponds well with ischemic/fibrotic infarction area due to CAD.104 There are only some 
few case-reports comparing LGE and corresponding microscopic fibrosis in explanted hearts 
from HCM-patients.30,31 The lack of existing data linking LGE-CMR with histology was the 
background for performing the study in Paper II where we found no relation between 
amount of fibrosis and LGE. Furthermore, enhanced LGE was not, in contrast to longitudinal 
septal strain, associated with arrhythmias.  
Different grey-scale thresholding methods have been used to define areas of LGE.90 The 
presence and amount (percentage of total LV mass) of LGE may either be judged visually or 
by using dedicated software.104 The quantification methods rely on the fact that LGE makes 
the scar brighter than normal myocardium. LGE has been defined as signal intensity of ≥2 SD 
above normal myocardium. In HCM-patients it has been stated that using the 2SD-method 
LGE will be overestimated, and thus, several studies now use the 5-6SD-method to measure 
LGE in HCM-patients.35,90,105 Moravsky et al described a good correlation between 6SD-
method and visual estimate.90 In the above-mentioned study by Chan et al, the authors used 
visual estimate to demonstrate an association between LGE and an increased risk of SCD.35 
In Paper II we used a visual estimate to measure the presence and amount of LGE and our 
results (presence of global LGE of 62%) corresponds well with others (presence of LGE of 
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56% and 41%).33,37 The presence of basal septal LGE of 52% in Paper II (11 of 21 patients) is 
also in the same range as the findings in a study by Kwon et al of 63% (38 of 60 patients).83 In 
our study 7 of the 8 patients without visualized LGE had microscopic fibrosis in the 
myectomy specimens. This means that visually estimated LGE-CMR does not reflect the total 
amount of myocardial fibrosis which may be responsible for malignant arrhythmias in HCM-
patients.  However, whether new methods are better correlated with both fibrosis and 
ventricular arrhythmias are yet to be answered. A new LGE-CMR method, T1-mapping and 
extracellular volume quantification, may be useful for the assessment of diffuse interstitial 
fibrosis.105 This method was not available at the time of our project.  
LGE-CMR is limited in clinical use both by methodological difficulties and restricted 
availability. MS Maron and Pandian pointed out in an editorial-comment of Di`Salvo et al`s 
echocardiographic study of 93 HCM-patients, “Is 2D echocardiographic strain ready for 
prime time?”106,107 In the study of Di`Salvo et al the patients with NSVT (26%) had lower 
longitudinal septal strain compared to the patients without NSVT, and the presence of 
longitudinal strain ≥-10% in >3 of 16 segments predicted NSVT independently with a 
sensitivity of 81% and specificity of 97%. These findings corresponds well with our findings 
both in Paper I and II, where patients with NSVT (24% and 25%, respectively) had 
longitudinal septal strain in the same area as Di`Salvo. In Paper I and II the echocardiographic 
findings were compared with microscopic fibrosis in operation specimens from the 
myectomized patients. The results demonstrated that patients with ventricular arrhythmias 
had higher amount of microscopic fibrosis compared to patients without arrhythmias, and 
when separating into replacement and interstitial type of fibrosis there was a significant 
association between reduced longitudinal septal strain and interstitial fibrosis. In Paper I 
reduced longitudinal septal strain was an independent predictor of ventricular arrhythmias 
in the total population of 63 patients, and in the histology-population of 24 patients both 
longitudinal septal strain and increased amount of interstitial fibrosis predicted ventricular 
arrhythmias significantly in a univariable logistic regression analysis. Although the numbers 
of patients are low in Paper I and II, longitudinal septal strain significantly predicted 
ventricular arrhythmias and detected microscopic fibrosis. This was in contrast to LGE-CMR, 
indicating that longitudinal septal strain is a more powerful tool to predict ventricular 
arrhythmias than visual estimated LGE. 
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8.4. Myocardial function 
Myocardial function evaluated by EF is normal or often supra-normal in patients with HCM. 
Patients with HCM have obviously reduced myocardial function due to several 
pathophysiological factors as myocyte hypertrophy, myocardial disarray, myocardial fibrosis, 
and sarcomere mutations associated with structural abnormalities and possible force 
generation deficiency. These factors may not influence on myocardial ability of reduction of 
LV cavity volume, and thereby EF is maintained. In all the four Papers mean EF was normal. 
Therefore, it is necessary with several non-invasive modalities to quantify myocardial 
function in HCM-patients. Normal LV systolic function is the result of deformation caused by 
synchronous contraction of myocardial fibres in different orientations.108 The LV long-axis is 
oriented from apex to base, the radial axis is perpendicular to the epicardium away from the 
cavity, and the circumferential axis is perpendicular to the radial and longitudinal directions 
and is orientated counterclockwise around the short-axis. The fibre orientation changes 
gradually from a right-handed helix (+60°) in the subendocardium to a left-handed helix (-
75°) in the subepicardium.109 The midwall-fibres are circumferentially oriented. During 
systole endo- and epicardial longitudinal fibre components contribute to long-axis 
contraction, while the midwall circumferential fibre components contribute to the reduction 
of the short-axis diameter. Both these mechanisms contribute to systolic wall thickening and 
a reduction of LV cavity volume. Additionally, there is long-axis torsion due to contraction of 
the obliquely orientated fibres.   The most widely used markers of global and regional LV 
function, ejection fraction (EF) and wall motion score index, utilize the reduction of cavity 
volume during LV systolic ejection, and visual evaluation of LV regional wall motion and 
thickening, respectively. Strain is a measure of deformation. In cardiac mechanics strain 
represents the fractional or percentage change in dimension, and is defined as tissue 
elongation in relation to end-diastolic length. Positive strain refers to elongation and 
negative strain to shortening. Strain is a vector that can be measured along any given axis. 
Quantification of myocardial strain along longitudinal and circumferential shortening and 
radial thickening, represent a measure of contractile function. In line with several other 
studies, the results in Paper I and II demonstrated that longitudinal function is 
46 
 
reduced22,28,110-112, and circumferential function is maintained.110,111 Some studies report 
decreased values of global circumferential function in HCM.22,112 In Paper I, II and III 
(unpublished results) mean global and septal longitudinal strain were reduced, although the 
level differed due to different patient populations. Global and septal circumferential strain 
reported in Paper II, were increased. In line with our results, Urbano-Moral et al found 
decreased longitudinal and increased circumferential 3D-strain and concluded that the 
extent of hypertrophy, not the fibrosis detected by LGE, was the primary factor altering 
global myocardial mechanics.113 
In an animal model with myosin-binding protein C-knockout mice there was substantial 
myoarchitectural disarray located in the mid-myocardium-subendocardium, and impairment 
of the transmural progression of helix angles from subepicardium to subendocardium.114 The 
mid-wall circumferential fibreorientation was retained. Urbano-Moral et al speculated that 
the longitudinal subendocardial muscle layers, which are responsible for most of the 
longitudinal deformation, are the most impaired functionally due to changed 
fibreorientation.113  
 
8.5. Septal reduction therapy 
The latest European guidelines equate PTSMA and myectomy as septal reduction therapy for 
obstructive HCM-patients with a resting or provoked LVOT gradient ≥50 mmHg and with 
symptoms (NYHA functional class III-IV) despite maximum tolerated medical therapy.5 
Myectomy is favoured if there are additional lesions requiring surgical intervention (mitral 
valve repair/replacement, papillary muscle intervention, CAD, or moderate to serious aortic 
valve disease). Due to the less invasive nature of PTSMA this procedure has gained 
popularity and in the recent years PTSMA has been performed more frequently than 
myectomy.  
In Paper IV we report persistent low LVOT gradient and symptomatic improvement, and 
good short and long outcome in a Scandinavian population of 279 obstructive HCM-patients. 
At publication time for this article (May 2011), this was the first international multi-centre 
long term outcome study of PTSMA. The main findings of this study, done at high-volume 
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PCI-centres and low/moderate-volume PTSMA-procedures (minimum of 10 PTSMA-
procedures per year), was low in-hospital mortality rate (0.3%) comparable to other PTSMA- 
studies.62,63 In June 2011 Nagueh et al published a multi-centre North-American long term 
outcome study of 874 PTSMA-treated patients.65 They reported 1-, 5-, and 9-years survival 
estimates of 97%, 86%, and 74%, comparable of the 1-, 5-, and 10-years survival estimates in 
Paper IV of 97%, 87%, and 67%. Ommen et al reported in 2005 1-, 5-, and 10-year overall 
survival after myectomy (n=289) of 98%, 96%, and 83%.52 In the same study non-operated 
obstructive HCM-patients (n=228) had 1-, 5-, and 10-years overall survival estimates of 90%, 
79%, and 61%.52  
There are no randomized trials comparing myectomy and PTSMA, but several meta analyses 
show equal symptom response and equal short- and long-term outcome.115 The residual 
LVOT gradient tends to be higher after PTSMA, and there are a higher proportion of patients 
needing a permanent pacemaker after PTSMA. Thus if myectomy was available in every 
centre for all patients; should all the obstructive HCM-patients be operated with myectomy? 
In the European guidelines myectomy is recommended if there are serious hypertrophy 
(≥30mm) and in young patients and children. Considering the nature of the PTSMA- and 
myectomy-procedure, it is reasonable to assume that myectomy is preferable in the patients 
with serious septal hypertrophy, but few studies support this statement. The guidelines 
recommend myectomy for children and young adults with obstructive HCM. As a 
consequence the literature lacks studies of PTSMA-procedures done at children and young 
adults.  
At Oslo University Hospital, Rikshospitalet, both PTSMA and myectomy are established 
procedures, and according to guidelines, the selection of treatment option is result of a 
comprehensive discussion among experienced HCM-experts. However, it is often difficult to 
predict the most suitable procedure, and there are no established prediction-factors 
favouring PTSMA or myectomy. In Paper III we used three different success-definitions 
based on earlier published studies; symptomatic, hemodynamic, and combined symptomatic 
and hemodynamic success one year after PTSMA.61,115,116 PTSMA is primarily a symptomatic 
treatment and studies report symptomatic improvement in 80-90% of the patients short and 
long time after PTSMA.61,62 When combining both optimal symptomatic response and 
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improvement of exercise capacity Faber et al published successful PTSMA in 43% of the 
patients.61  
LV relaxation, filling and compliance are frequently impaired in patients with HCM, and these 
factors are a major contributor to symptoms in these patients.117-119 Diastolic dysfunction is 
a result of the underlying disease process in HCM and may represents a complex interaction 
of prolonged ventricular relaxation, myocardial fibrosis, and increased chamber stiffness 
leading to chronically elevated left ventricular filling pressures, which in turn result in left 
atrial enlargement. Maron et al described in 1987 impaired diastolic dysfunction assessed by 
Doppler echocardiography compared to normal.120 Catheter measured LV end-diastolic 
pressure in obstructive HCM-patients is reported to be 22-25 mmHg.121-123 In contrast to 
other cardiac diseases, in HCM-patients there is only a modest correlation between Doppler 
echocardiographic estimates of LV filling pressure using transmitral flow and mitral annular 
velocities, and directed catheter measured LV filling pressure.117  
In the total population in Paper III age at intervention and baseline echocardiographic 
diastolic parameters were in the same range as earlier studies.117,120,124,125 In Paper III we 
conclude that non-successful hemodynamic response was associated with worse diastolic 
function and younger age at intervention time. These parameters indicate that patients with 
more serious phenotype of HCM are more un-responsive of successful intervention with 
PTSMA. Sitges et al compared echocardiographic diastolic parameters before and 5 months 
after PTSMA and myectomy.124 The parameters showed equal improvement of diastolic 
function after removal of LVOT obstruction after PTSMA and myectomy. To our knowledge 
we are the first to publish worse baseline diastolic parameters in patients with 
hemodynamic non-successful PTSMA.       
 
8.6. Future perspective 
One of the main finding in this thesis was the importance of differentiation between 
different types of fibrosis. Our studies indicate that different types of fibrosis have different 
clinical effects. Thus it is not sufficient to report total amount of fibrosis. As the type of 
fibrosis is associated with clinical effects, the pathophysiology of different types of fibrosis 
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should be examined at a molecular level. In our hands strain by STE was a powerful method 
to assess fibrosis and to predict ventricular arrhythmias. This should be performed in larger 
studies.  
Given the current guidelines it is almost impossible to perform randomised controlled trials 
comparing myectomy and PTSMA. However, there might be sub-groups which might benefit 
on PTSMA and future studies should aim to identify these patients.
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9. CONCLUSIONS 
The main conclusions from this thesis are as follows: 
x In HCM reduced septal myocardial function and interstitial fibrosis predicts 
ventricular arrhythmias. 
 
x Reduced interventricular septal strain correlates with the extent of histological 
fibrosis in HCM-patients. 
 
x Younger age at intervention and pre-procedural diastolic dysfunction is associated 
with non-successful PTSMA. 
 
x PTSMA can be performed with low in-hospital mortality and with sustained 
symptomatic and hemodynamic effects with 10-year survival rate comparable to 
background population. 
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